Krystal Biotech (4KB) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

4KB Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Krystal

Biotech

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

4KB Stock 12 Month Forecast

Average Price Target

€350.22

▲(18.36% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Krystal Biotech in the last 3 months. The average price target is €350.22 with a high forecast of €411.71 and a low forecast of €313.56. The average price target represents a 18.36% change from the last price of €295.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"124":"€124","196":"€196","268":"€268","340":"€340","412":"€412"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":411.71136612,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€411.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":350.215238016,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€350.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":313.56076618,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€313.56</span>\n  </div></div>","useHTML":true}}],"tickPositions":[124,196,268,340,412],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,314.6,322.0701050861539,329.5402101723077,337.01031525846156,344.48042034461537,351.95052543076923,359.4206305169231,366.8907356030769,374.36084068923077,381.83094577538463,389.30105086153844,396.7711559476923,404.2412610338461,{"y":411.71136612,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,314.6,317.3396336935385,320.0792673870769,322.8189010806154,325.5585347741539,328.29816846769234,331.0378021612308,333.77743585476924,336.5170695483077,339.25670324184614,341.99633693538465,344.7359706289231,347.47560432246155,{"y":350.215238016,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,314.6,314.5200589369231,314.4401178738462,314.36017681076925,314.2802357476923,314.2002946846154,314.12035362153847,314.0404125584615,313.9604714953846,313.8805304323077,313.80058936923075,313.7206483061538,313.6407072430769,{"y":313.56076618,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":133.25,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.05,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":162.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.65,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":214.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":237,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":230.8,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222.3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":219.1,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":260,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":330.2,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":314.6,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€411.71

Average Price Target€350.22

Lowest Price Target€313.56

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yigal Nochomovitz

Citi

€328.33→€335.28

Buy

13.31%

Upside

Reiterated

08/04/26

Citi Reaffirms Their Buy Rating on Krystal Biotech (KRYS)

Ritu Baral

TD Cowen

€350.04

Buy

18.30%

Upside

Reiterated

08/03/26

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (NASDAQ: CRSP), Supernus Pharmaceuticals (NASDAQ: SUPN) and Krystal Biotech (NASDAQ: KRYS)

Joseph Pantginis

H.C. Wainwright

€313.56

Buy

5.97%

Upside

Reiterated

08/03/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Sami Corwin

William Blair

―

Buy

―

Reiterated

08/03/26

Analyst Backs Krystal with Buy Rating on Vyjuvek Launch Momentum and Rare-Disease Pipeline Upside

Alec Stranahan

Bank of America Securities

€343.96→€340.49

Buy

15.07%

Upside

Reiterated

08/03/26

Alec Stranahan Maintains Buy on Krystal Biotech, Slightly Lowers Price Target to $392 Amid Strong Vyjuvek Momentum and Pipeline Catalysts

Roger Song

Jefferies

€411.71

Buy

39.14%

Upside

Assigned

07/13/26

Analysts Offer Insights on Healthcare Companies: Genmab (NASDAQ: GMAB), Krystal Biotech (NASDAQ: KRYS) and Denali Therapeutics (NASDAQ: DNLI)

Gavin Clark-Gartner

Evercore ISI

€256.23→€260.58

Buy

-11.94%

Downside

Reiterated

05/05/26

Krystal Biotech price target raised to $300 from $295 at Evercore ISIKrystal Biotech price target raised to $300 from $295 at Evercore ISI

Debjit Chattopadhyay

Guggenheim

€246.68

Buy

-16.63%

Downside

Reiterated

05/04/26

Guggenheim Sticks to Their Buy Rating for Krystal Biotech (KRYS)

William Maughan

Clear Street

€293.58→€270.13

Buy

-8.71%

Downside

Reiterated

05/04/26

Krystal Biotech price target lowered to $311 from $338 at Clear StreetKrystal Biotech price target lowered to $311 from $338 at Clear Street

Geulah Livshits

Chardan Capital

€280.55

Buy

-5.19%

Downside

Reiterated

05/04/26

Chardan Capital Keeps Their Buy Rating on Krystal Biotech (KRYS)

Kalpit Patel

Wolfe Research

―

Hold

―

Initiated

03/26/26

Krystal Biotech: Valuation Reflects Pipeline Optimism Amid Dosing and Efficacy Risks, Justifying a Hold Rating

Andrea Tan

Goldman Sachs

€178.93→€284.03

Buy

-4.01%

Downside

Reiterated

01/30/26

Krystal Biotech price target raised to $327 from $206 at Goldman SachsKrystal Biotech price target raised to $327 from $206 at Goldman Sachs

Joshua Schimmer

Cantor Fitzgerald

€186.75

Buy

-36.89%

Downside

Reiterated

09/07/25

Cantor Fitzgerald Keeps Their Buy Rating on Krystal Biotech (KRYS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yigal Nochomovitz

Citi

€328.33→€335.28

Buy

13.31%

Upside

Reiterated

08/04/26

Citi Reaffirms Their Buy Rating on Krystal Biotech (KRYS)

Ritu Baral

TD Cowen

€350.04

Buy

18.30%

Upside

Reiterated

08/03/26

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (NASDAQ: CRSP), Supernus Pharmaceuticals (NASDAQ: SUPN) and Krystal Biotech (NASDAQ: KRYS)

Joseph Pantginis

H.C. Wainwright

€313.56

Buy

5.97%

Upside

Reiterated

08/03/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Sami Corwin

William Blair

―

Buy

―

Reiterated

08/03/26

Analyst Backs Krystal with Buy Rating on Vyjuvek Launch Momentum and Rare-Disease Pipeline Upside

Alec Stranahan

Bank of America Securities

€343.96→€340.49

Buy

15.07%

Upside

Reiterated

08/03/26

Alec Stranahan Maintains Buy on Krystal Biotech, Slightly Lowers Price Target to $392 Amid Strong Vyjuvek Momentum and Pipeline Catalysts

Roger Song

Jefferies

€411.71

Buy

39.14%

Upside

Assigned

07/13/26

Analysts Offer Insights on Healthcare Companies: Genmab (NASDAQ: GMAB), Krystal Biotech (NASDAQ: KRYS) and Denali Therapeutics (NASDAQ: DNLI)

Gavin Clark-Gartner

Evercore ISI

€256.23→€260.58

Buy

-11.94%

Downside

Reiterated

05/05/26

Krystal Biotech price target raised to $300 from $295 at Evercore ISIKrystal Biotech price target raised to $300 from $295 at Evercore ISI

Debjit Chattopadhyay

Guggenheim

€246.68

Buy

-16.63%

Downside

Reiterated

05/04/26

Guggenheim Sticks to Their Buy Rating for Krystal Biotech (KRYS)

William Maughan

Clear Street

€293.58→€270.13

Buy

-8.71%

Downside

Reiterated

05/04/26

Krystal Biotech price target lowered to $311 from $338 at Clear StreetKrystal Biotech price target lowered to $311 from $338 at Clear Street

Geulah Livshits

Chardan Capital

€280.55

Buy

-5.19%

Downside

Reiterated

05/04/26

Chardan Capital Keeps Their Buy Rating on Krystal Biotech (KRYS)

Kalpit Patel

Wolfe Research

―

Hold

―

Initiated

03/26/26

Krystal Biotech: Valuation Reflects Pipeline Optimism Amid Dosing and Efficacy Risks, Justifying a Hold Rating

Andrea Tan

Goldman Sachs

€178.93→€284.03

Buy

-4.01%

Downside

Reiterated

01/30/26

Krystal Biotech price target raised to $327 from $206 at Goldman SachsKrystal Biotech price target raised to $327 from $206 at Goldman Sachs

Joshua Schimmer

Cantor Fitzgerald

€186.75

Buy

-36.89%

Downside

Reiterated

09/07/25

Cantor Fitzgerald Keeps Their Buy Rating on Krystal Biotech (KRYS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

TNYATenaya Therapeutics

JBIOJade Biosciences

GHRSGH Research

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Krystal Biotech

3 Months

Geulah LivshitsChardan Capital

Success Rate

13/20 ratings generated profit

Average Return

+10.83%

Copying Geulah Livshits's trades and holding each position for 3 Months would result in 65.00% of your transactions generating a profit, with an average return of +10.83% per trade.

1 Year

Geulah LivshitsChardan Capital

Success Rate

19/20 ratings generated profit

Average Return

+46.97%

Copying Geulah Livshits's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +46.97% per trade.

2 Years

Geulah LivshitsChardan Capital

Success Rate

20/20 ratings generated profit

Average Return

+93.27%

Copying Geulah Livshits's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +93.27% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4KB Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4KB has received 11 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 4KB average Analyst price target in the past 3 months is 350.22.

Each month's total comprises the sum of three months' worth of ratings.

4KB Financial Forecast

4KB Earnings Forecast

Next quarter’s earnings estimate for 4KB is €1.61 with a range of €1.39 to €1.87. The previous quarter’s EPS was €1.55. 4KB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 45.99% of the time in the same period. In the last calendar year 4KB has Performed in-line its overall industry.

4KB Sales Forecast

Next quarter’s sales forecast for 4KB is €111.06M with a range of €106.05M to €116.64M. The previous quarter’s sales results were €103.47M. 4KB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 30.22% of the time in the same period. In the last calendar year 4KB has Performed in-line its overall industry.

4KB Stock Forecast FAQ

What is DE:4KB’s average 12-month price target, according to analysts?

Based on analyst ratings, Krystal Biotech’s 12-month average price target is 350.22.

What is DE:4KB’s upside potential, based on the analysts’ average price target?

Krystal Biotech has 18.36% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Krystal Biotech a Buy, Sell or Hold?

Krystal Biotech has a consensus rating of Strong Buy, which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is Krystal Biotech’s share price target?

The average share price target for Krystal Biotech is 350.22. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €411.71 ,and the lowest forecast is €313.56. The average share price target represents 18.36% Increase from the current price of €295.9.

What do analysts say about Krystal Biotech?

Krystal Biotech’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of Krystal Biotech?

To buy shares of DE:4KB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Krystal Biotech (4KB) Stock Forecast & Price Target

4KB Analyst Ratings

4KB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Krystal Biotech

4KB Analyst Recommendation Trends

4KB Financial Forecast

4KB Earnings Forecast

4KB Sales Forecast

4KB Stock Forecast FAQ

Detailed List of Analyst Forecasts